title: Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
authors.forename: Pietro
authors.initials: P
authors.lastname: Leccese
authors.forename: Loredana
authors.initials: L
authors.lastname: Latanza
authors.forename: Salvatore
authors.initials: S
authors.lastname: D'Angelo
authors.forename: Angela
authors.initials: A
authors.lastname: Padula
authors.forename: Ignazio
authors.initials: I
authors.lastname: Olivieri
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy*; D004351:Drug Resistance; D006801:Humans; D000069285:Infliximab; D008297:Male; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000068879:Adalimumab